Welcome to Oncolytics Insights. Here we will provide commentary on recent news, presentations and happenings related to Oncolytics and our development programs.

AACR 2019 Snapshot: A First Look at Predictive Biomarker Data from a Combination Study of Pelareorep + Keytruda® in Pancreatic Cancer

AACR 2019 was an important conference for us. We’ve been investigating the potential utility of a biomarker to help predict a patients response to receiving pelareorep combined with other immunotherapies, such as checkpoint inhibitors. This study is a first look at the utility of T cell clonality as a predictor of response to therapy, and we’re very excited about it.